New drug BB102 takes on Hard-to-Treat liver cancer
Disease control
Not yet recruiting
This Phase 2 trial tests BB102, a targeted drug that blocks a protein called FGFR4, in 60 adults with advanced liver cancer that has not responded to standard treatments. Participants must have a specific genetic marker (FGF19 overexpression). The study will measure how well the …
Phase: PHASE2 • Sponsor: Broadenbio Ltd., Co. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC